REGEN BIOPHARMA, INC. — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7cd6766f-4270-4c86-93a6-3b855a475f08/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-1.3M | 2024-04-01 – 2025-09-30 | evidence 0001493152-26-022924 |
| FY 2024 | $-668.3k | 2023-10-01 – 2024-09-30 | evidence 0001641172-25-009968 |
| FY 2023 | $1.2M | 2022-10-01 – 2023-09-30 | evidence 0001607062-23-000524 |
| FY 2022 | $2.4M | 2021-10-01 – 2022-09-30 | evidence 0001607062-22-000694 |
| FY 2021 | $-6.8M | 2020-10-01 – 2021-09-30 | evidence 0001607062-21-000641 |
| FY 2020 | $3.4M | 2019-10-01 – 2020-09-30 | evidence 0001607062-21-000250 |
| FY 2019 | $-2.6M | 2018-10-01 – 2019-09-30 | evidence 0001607062-21-000165 |
| FY 2018 | $-4.7M | 2017-10-01 – 2018-09-30 | evidence 0001607062-18-000491 |
| FY 2017 | $-5.8M | 2016-10-01 – 2017-09-30 | evidence 0001607062-18-000491 |
| FY 2016 | $-7.8M | 2015-10-01 – 2016-09-30 | evidence 0001607062-16-001092 |
| FY 2015 | $-15.4M | 2012-04-24 – 2016-03-31 | evidence 0001607062-16-000813 |
| FY 2014 | $-756.4k | 2013-10-01 – 2014-09-30 | evidence 0001607062-14-000203 |
| FY 2013 | $-918.0k | 2012-04-24 – 2014-03-31 | evidence 0001554795-14-000345 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
REGEN BIOPHARMA, INC. — all facts · Revenue · Operating Income